S
Stephen J. W. Evans
Researcher at University of London
Publications - 217
Citations - 22005
Stephen J. W. Evans is an academic researcher from University of London. The author has contributed to research in topics: Cohort study & Population. The author has an hindex of 58, co-authored 198 publications receiving 16771 citations. Previous affiliations of Stephen J. W. Evans include University of Oxford.
Papers
More filters
Journal ArticleDOI
Factors associated with COVID-19-related death using OpenSAFELY.
Elizabeth A. Williamson,Alex J Walker,Krishnan Bhaskaran,Seb Bacon,Chris Bates,Caroline E Morton,Helen J Curtis,Amir Mehrkar,David M. Evans,Peter Inglesby,Jonathan Cockburn,Helen Mcdonald,Brian MacKenna,Laurie A. Tomlinson,Ian J. Douglas,Christopher T Rentsch,Rohini Mathur,Angel Y S Wong,Richard Grieve,David G. Harrison,Harriet Forbes,Anna Schultze,Richard Croker,John Parry,Frank Hester,Sam Harper,Rafael Perera,Stephen J. W. Evans,Liam Smeeth,Ben Goldacre +29 more
TL;DR: A range of clinical factors associated with COVID-19-related death is quantified in one of the largest cohort studies on this topic so far and includes people of white ethnicity, Black and South Asian people were at higher risk, even after adjustment for other factors.
Journal ArticleDOI
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.
TL;DR: An updated extension of the CONSORT checklist for reporting noninferiority and equivalence trials is presented, based on the 2010 version of theconsORT Statement and the 2008 CONSORT Statement for the reporting of abstracts, and illustrative examples and explanations for those items that differ from the main 2010consORT checklist are provided.
Journal ArticleDOI
Better reporting of harms in randomized trials: an extension of the CONSORT statement.
John P. A. Ioannidis,Stephen J. W. Evans,Peter C Gøtzsche,Robert T O'Neill,Douglas G. Altman,Kenneth F. Schulz,David Moher +6 more
TL;DR: This work searched MEDLINE, EMBASE, Web of Science, and the Cochrane Library using a wide array of terms related to harms and identified pertinent evidence and made recommendations on the appropriate reporting of harms in RCTs.
Journal ArticleDOI
Interpretation of the evidence for the efficacy and safety of statin therapy.
Rory Collins,Christina Reith,Jonathan Emberson,Jane Armitage,Colin Baigent,Lisa Blackwell,Roger S. Blumenthal,John Danesh,George Davey Smith,David L. DeMets,Stephen J. W. Evans,Malcolm Law,Stephen MacMahon,Seth S. Martin,Bruce Neal,Neil R Poulter,David Preiss,Paul M. Ridker,Ian Roberts,Anthony Rodgers,Peter Sandercock,Kenneth F. Schulz,Peter S. Sever,John Simes,Liam Smeeth,Nicholas J. Wald,Salim Yusuf,Richard Peto +27 more
TL;DR: The large-scale evidence from randomised trials indicates that it is unlikely that large absolute excesses in other serious adverse events still await discovery, and any further findings that emerge about the effects of statin therapy would not be expected to alter materially the balance of benefits and harms.
Journal ArticleDOI
Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports
TL;DR: The process of generating ‘signals’ of possible unrecognized hazards from spontaneous adverse drug reaction reporting data has been likened to looking for a needle in a haystack but statistical approaches to the data have been underutilised.